We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





Bosch Exhibits Vivalytic All-in-One Analyzer for PCR Rapid Tests at MEDICA 2021

By LabMedica International staff writers
Posted on 18 Nov 2021

Bosch Healthcare Solutions GmbH (Waiblingen, Germany) exhibited its universal platform for molecular diagnostics that allows users to analyze a wide variety of sample materials in a fully automated way in a short time at MEDICA 2021. More...

The Vivalytic Analyzer from Bosch that was on display at the event allows infectious diseases to be diagnosed more quickly and easily than is the case today with manual tests in hospitals, laboratories, and medical practices. The platform combines different analysis methods in one device and is open to providers of further tests. The platform unites a wide spectrum of tests with a varying number of clinically relevant parameters on one device. The Vivalytic Analyzer enables fully automated PCR testing in laboratory quality – fast and directly at the point of care. The Vivalytic system consists of just a compact analysis device and cartridges the size of a smartphone. This enables rapid PCR tests to be carried out directly on site.

The Vivalytic Analyzer unites a wide variety of innovative technologies in one compact device. With only a touch display, a slot for inserting the test cartridge, a button and a scanner, the Analyser is very intuitive to use. This minimalistic design makes the Vivalytic system very user-friendly: medical professionals require only minimal training to be able to safely operate the Analyzer. Different types of samples can be tested fully automated with the Vivalytic Analyzer. The innovative technology reduces the need for manual preparation. The analyzer takes over this task before the analysis and evaluation takes place.

Bosch has developed a new rapid test for its Vivalytic analysis device to detect the SARS-CoV-2 pathogen. The test provides a reliable result in 39 minutes and is currently the fastest polymerase chain reaction (PCR) test worldwide. Results for positive samples are even delivered in less than 30 minutes. As a multiplex test, it simultaneously checks patient samples for the SARS-CoV-2 virus and nine other respiratory diseases in under two and a half hours. Bosch’s new rapid test is predestined for decentralized use in mobile test centers at freeway service stations or in airports. People who take the test can obtain a reliable result while at the testing site. Available now in Europe, the CE-approved test helps avoid time in quarantine, relieve laboratories, and make travel and work safer again.

Related Links:
Bosch Healthcare Solutions GmbH 


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Uric Acid Meter
PA-16
New
Mini Vortex Mixer
Vornado
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.